Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therap...
| Authors: | ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2025 |
| Country: | España |
| Institution: | Universitat Pompeu Fabra |
| Repository: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:dnet:rdupf_______::36541b6c94caaaf71e6af960ab2c0c21 |
| Online Access: | https://hdl.handle.net/10230/73171 http://dx.doi.org/10.1007/s12094-025-03865-6 |
| Access Level: | Open access |
| Keyword: | Biomarkers Claudin 18.2 Gastroesophageal carcinoma HER2 MSI/dMMR PD-L1 |
| _version_ | 1878731352317100032 |
|---|---|
| author | Alsina Maqueda, Maria |
| author2 | Teijo Quintáns, Ana Cuatrecasas, Miriam Fernández Aceñero, María Jesús Fernández Montes, Ana Gómez Martín, Carlos Jiménez Fonseca, Paula Martínez Ciarpaglini, Carolina Rivera Herrero, Fernando Iglesias Coma, Mar |
| author2_role | author author author author author author author author author |
| author_browse | Alsina Maqueda, Maria Cuatrecasas, Miriam Fernández Aceñero, María Jesús Fernández Montes, Ana Gómez Martín, Carlos Iglesias Coma, Mar Jiménez Fonseca, Paula Martínez Ciarpaglini, Carolina Rivera Herrero, Fernando Teijo Quintáns, Ana |
| author_facet | Alsina Maqueda, Maria Teijo Quintáns, Ana Cuatrecasas, Miriam Fernández Aceñero, María Jesús Fernández Montes, Ana Gómez Martín, Carlos Jiménez Fonseca, Paula Martínez Ciarpaglini, Carolina Rivera Herrero, Fernando Iglesias Coma, Mar |
| author_role | author |
| collection | Repositorio Digital de la UPF |
| description | Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_2ddc7c586d4497b049b45a1e93c36fd2 |
| institution | Universitat Pompeu Fabra |
| instname_str | Universitat Pompeu Fabra |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:dnet:rdupf_______::36541b6c94caaaf71e6af960ab2c0c21 |
| publishDate | 2025 |
| publishDateSort | 2025 |
| publisher | Springer |
| publisherStr | Springer |
| reponame_str | Repositorio Digital de la UPF |
| spelling | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) Alsina Maqueda, Maria Teijo Quintáns, Ana Cuatrecasas, Miriam Fernández Aceñero, María Jesús Fernández Montes, Ana Gómez Martín, Carlos Jiménez Fonseca, Paula Martínez Ciarpaglini, Carolina Rivera Herrero, Fernando Iglesias Coma, Mar Biomarkers Claudin 18.2 Gastroesophageal carcinoma HER2 MSI/dMMR PD-L1 Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care. Springer https://hdl.handle.net/10230/73171 http://dx.doi.org/10.1007/s12094-025-03865-6 |
| spellingShingle | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) Alsina Maqueda, Maria Biomarkers Claudin 18.2 Gastroesophageal carcinoma HER2 MSI/dMMR PD-L1 |
| status_str | publishedVersion |
| title | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) |
| title_full | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) |
| title_fullStr | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) |
| title_full_unstemmed | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) |
| title_short | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) |
| title_sort | Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) |
| topic | Biomarkers Claudin 18.2 Gastroesophageal carcinoma HER2 MSI/dMMR PD-L1 |
| topic_facet | Biomarkers Claudin 18.2 Gastroesophageal carcinoma HER2 MSI/dMMR PD-L1 |
| url | https://hdl.handle.net/10230/73171 http://dx.doi.org/10.1007/s12094-025-03865-6 |